Literature DB >> 8493574

Identification of the von Hippel-Lindau disease tumor suppressor gene.

F Latif1, K Tory, J Gnarra, M Yao, F M Duh, M L Orcutt, T Stackhouse, I Kuzmin, W Modi, L Geil.   

Abstract

A gene discovered by positional cloning has been identified as the von Hippel-Lindau (VHL) disease tumor suppressor gene. A restriction fragment encompassing the gene showed rearrangements in 28 of 221 VHL kindreds. Eighteen of these rearrangements were due to deletions in the candidate gene, including three large nonoverlapping deletions. Intragenic mutations were detected in cell lines derived from VHL patients and from sporadic renal cell carcinomas. The VHL gene is evolutionarily conserved and encodes two widely expressed transcripts of approximately 6 and 6.5 kilobases. The partial sequence of the inferred gene product shows no homology to other proteins, except for an acidic repeat domain found in the procyclic surface membrane glycoprotein of Trypanosoma brucei.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8493574     DOI: 10.1126/science.8493574

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  657 in total

1.  Tumor suppressors on 3p: a neoclassic quartet.

Authors:  K Huebner
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

2.  Integrative epigenomic and genomic analysis of malignant pheochromocytoma.

Authors:  Johanna Sandgren; Robin Andersson; Alvaro Rada-Iglesias; Stefan Enroth; Goran Akerstrom; Jan P Dumanski; Jan Komorowski; Gunnar Westin; Claes Wadelius
Journal:  Exp Mol Med       Date:  2010-07-31       Impact factor: 8.718

3.  Neurological surgery at the National Institutes of Health.

Authors:  Gautam U Mehta; John D Heiss; John K Park; Ashok R Asthagiri; Kareem A Zaghloul; Russell R Lonser
Journal:  World Neurosurg       Date:  2010-07       Impact factor: 2.104

Review 4.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 5.  Recent advances in intradural spinal tumors.

Authors:  Muhammad M Abd-El-Barr; Kevin T Huang; Ziev B Moses; J Bryan Iorgulescu; John H Chi
Journal:  Neuro Oncol       Date:  2018-05-18       Impact factor: 12.300

6.  Von Hippel-Lindau gene deletion and expression of hypoxia-inducible factor and ubiquitin in optic nerve hemangioma.

Authors:  Chi-Chao Chan; Youn-Soo Lee; Zhengping Zhuang; Joseph Hackett; Emily Y Chew
Journal:  Trans Am Ophthalmol Soc       Date:  2004

7.  von Hippel-Lindau protein-mediated repression of tumor necrosis factor alpha translation revealed through use of cDNA arrays.

Authors:  Stefanie Galbán; Jinshui Fan; Jennifer L Martindale; Chris Cheadle; Bryan Hoffman; Michael P Woods; Gretchen Temeles; Jürgen Brieger; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-04       Impact factor: 4.272

8.  von Hippel-Lindau disease type 2A in a family with a duplicated 21-base-pair in-frame insertion mutation in the VHL gene.

Authors:  Yasuhiro Miyagawa; Mitsuru Nakazawa; Yasuko Noda; Shoichi Ito; Hiroshi Ohguro
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-02-20       Impact factor: 3.117

9.  Early-onset renal cell carcinoma as a novel extraparaganglial component of SDHB-associated heritable paraganglioma.

Authors:  Sakari Vanharanta; Mary Buchta; Sarah R McWhinney; Sanna K Virta; Mariola Peçzkowska; Carl D Morrison; Rainer Lehtonen; Andrzej Januszewicz; Heikki Järvinen; Matti Juhola; Jukka-Pekka Mecklin; Eero Pukkala; Riitta Herva; Maija Kiuru; Nina N Nupponen; Lauri A Aaltonen; Hartmut P H Neumann; Charis Eng
Journal:  Am J Hum Genet       Date:  2003-12-18       Impact factor: 11.025

10.  Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism.

Authors:  Jordan M Thompson; Alejandro Alvarez; Monika K Singha; Matthew W Pavesic; Quy H Nguyen; Luke J Nelson; David A Fruman; Olga V Razorenova
Journal:  Mol Cancer Ther       Date:  2018-05-02       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.